Effect of memantine treatment on regional cortical metabolism in alzheimer's disease

American Journal of Geriatric Psychiatry

Volumn 18, Issue 7, 2010, Pages 606-614

  Sultzer, David L ^a,b   Melrose, Rebecca J ^a,b   Harwood, Dylan G ^a,b   Campa, Olivia ^b   Mandelkern, Mark A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Alzheimer s disease; memantine; PET; therapeutics

Indexed keywords

DONEPEZIL; FLUORODEOXYGLUCOSE F 18; MEMANTINE; DOPAMINE RECEPTOR STIMULATING AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; OUTPATIENT; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; TEMPORAL LOBE; TREATMENT DURATION; TREATMENT RESPONSE; DRUG EFFECTS; METABOLISM; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBRAL CORTEX; DOPAMINE AGENTS; FEMALE; HUMANS; MALE; MEMANTINE; NEUROPSYCHOLOGICAL TESTS; PARIETAL LOBE; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; TEMPORAL LOBE;

EID: 77954332508     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e3181ca3a4e     Document Type: Article

References (37)

1. Fleisher AS, Raman R, Siemers ER, et al: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65:1031-1038
2. Jack CR Jr, Slomkowski M, Gracon SI, et al: MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003; 60:253-260
3. Reisberg B, Doody R, Stoffler A, et al: Memantine in moderate-to-severe Alzheimer s disease. N Engl J Med 2003; 348:1333-1341
4. Tariot PN, Farlow MR, Grossberg GT, et al: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324
5. Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer s disease. CNS Drug Rev 2003; 9:275-308
6. Parsons CG, Stoffler A, Danysz W: Memantine: a NMDA receptor antagonist that improves memory by restoration of ho-meostasis in the glutamatergic system\too little activation is bad, too much is even worse. Neuropharmacology 2007; 53: 699-723
7. Procter A: Abnormalities in non-cholinergic neurotransmitter systems in Alzheimer s disease, in Dementia. Edited by O'Brien J, Ames D, Burns A. London, Arnold, 2000, pp 433-442
8. Minkeviciene R, Banerjee P, Tanila H: Memantine improves spatial learning in a transgenic mouse model of Alzheimer s disease. Pharmacol Biochem Behav 2004; 77:191-197
9. Herholz K, Carter SF, Jones M: Positron emission tomography imaging in dementia. Br J Radiol 2007; 80:S160-S167
10. Drzezga A, Grimmer T, Riemenschneider M, et al: Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J Nucl Med 2005; 46:1625-1632
11. Anchisi D, Borroni B, Francheschi M, et al: Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005; 62:1728-1733
12. Engler H, Forsberg A, Almkvist O, et al: Two-year follow-up of amyloid deposition in patients with Alzheimer s disease. Brain 2006; 129:2856-2866
13. Hirono N, Hashimoto M, Ishii K, et al: One-year change in cerebral glucose metabolism in patients with Alzheimer s disease. J Neuropsychiatry Clin Neurosci 2004; 16:488-492
14. Sultzer DL, Brown C, Mandelkern MA, et al: Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer s disease. Am J Psychiatry 2003; 160:341-349
15. Melrose RJ, Campa OM, Harwood DG, et al: The neural correlates of naming and fluency deficits in Alzheimer s disease: a FDG-PET study. Int J Geriatr Psychiatry 2009; 24:885-893
16. Stefanova E, Wall A, Almkvist O, et al: Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer s disease. J Neural Transm 2006; 113:205-218
17. Murray AD, Staff RT, Ahearn TS, et al: Tau aggregation inhibitor therapy with Rember changes glucose metabolism in the medial temporal lobes in mild and moderate Alzheimer s disease. Alzheimer Dementia 2008; 4(suppl 2):T786-T787 (Abstract)
18. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer s Disease. Neurology 1984; 34:939-944
19. Folstein M, Folstein S, McHugh P: "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
20. Mattis S: Dementia Rating Scale: Professional Manual. Odessa, FL, Psychological Assessment Resource, Inc, 1988
21. Sultzer DL, Levin HS, Mahler ME, et al: Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neu-robehavioral Rating Scale. J Am Geriatr Soc 1992; 40:549-555
22. Mattis S: Dementia rating scale, in Handbook of Psychiatric Measures, 2nd ed. Edited by Rush AJ, First MB, Blacker D. Washington, DC, American Psychiatric Publishing, Inc, 2008, pp 407-410
23. Sultzer DL, Berisford MA, Gunay I: The Neurobehavioral Rating Scale: reliability in patients with dementia. J Psychiatr Res 1995; 29:185-191
24. Hamacher K, Coenen HH, Stocklin G: Efficient stereospecific synthesis of no-carrier-added 2-18F-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235-238
25. Maldjian JA, Laurienti PJ, Kraft RA, et al: An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003; 19:1233-1239
26. Alexander GE, Chen K, Pietrini P, et al: Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer s disease treatment studies. Am J Psychiatry 2002; 159:738-745
27. Potkin SG, Anand R, Fleming K, et al: Brain metabolic and clinical effects of rivastigmine in Alzheimer s disease. Int J Neuropsycho-pharmacol 2001; 4:223-230
28. Maquet P, Dive D, Salmon E, et al: Reproducibility of cerebral glucose utilization measured by PET and the 18F-2-fluoro-2-deoxy-D-glucose method in resting, healthy human subjects. Eur J Nucl Med 1990; 16:267-273
29. Mega MS, Dinov ID, Porter V, et al: Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglu-cose f 18 positron emission tomographic study. Arch Neurol 2005; 62:721-728
30. Schmidt RR, S, Pendl B, Ofner P, et al: Memantine effects on brain volume, glucose metabolism and cognition in AD patients\a randomized, double-blind, placebo-controlled neuroimaging pilot study. J Neurol Neurosurg Psychiatry 2008; 79:1312-1317
31. Weiner M, Graham SM, Hofbauer RK, et al: Memantine treatment in patients with Alzheimer s disease is associated with a slower right hippocampal volume loss: an open-label, multi-center trial. Presented at the International Conference on Alzheimer s Disease. Chicago, IL, 2008
32. Couratier P, Lesort M, Sindou P, et al: Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxic-ity. Mol Chem Neuropathol 1996; 27:259-273 (Pubitemid 26142650)
33. Hirao K, Ohnishi T, Matsuda H, et al: Functional interactions between entorhinal cortex and posterior cingulate cortex at the very early stage of Alzheimer s disease using brain perfusion single-photon emission computed tomography. Nucl Med Com-mun 2006; 27:151-156
34. Jobst KA, Smith AD, Barker CS, et al: Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer s disease. J Neurol Neurosurg Psychiatry 1992; 55:190-194
35. Chetelat G, Desgranges B, Landeau B, et al: Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer s disease. Brain 2008; 131:60-71
36. Meguro K, Blaizot X, Kondoh Y, et al: Neocortical and hippocam-pal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer s disease. Brain 1999; 122:1519-1531
37. Sultzer DL, Monserratt LM, Harwood DG, et al: Regional cortical metabolism and medication treatment response in Alzheimer s disease. (Abstract) Alzheimer Dementia 2006; 2(suppl 1):S619